1.
Marsden D.
Brain pigment and its relation to brain catecholamines.
Lancet 1965; 10:475-76.
2.
Graham DG.
On the origin and significance of neuromelanin.
Arch Pathol Lab Med 1979; 103:359-62.
3.
Bazelon M,
Fenichel GM,
Randall J.
Studies on neuromelanin: I.
A melanin system in the human adult brainstem.
Neurology 1967; 17:512-18.
4.
Enochs WS,
Hyslop WB,
Bennett HF,
et al.
Sources of the increased longitudinal relaxation rates observed in melanotic melanoma: an in vitro study of synthetic melanins.
Invest Radiol 1997; 24:794-804.
5.
Enochs WS,
Petherick P,
Bogdanova A,
et al.
Paramagnetic metal scavenging by melanin: MR imaging.
Radiology 1997; 204:417-23.
6.
Sasaki M,
Shibata E,
Tohyama K,
et al.
Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease.
Neuroreport 2006; 17:1215-8.
7.
Nakane T,
Nihashi T,
Kawai H,
et al.
Visualization of neuromelanin in the Substantia nigra and locus ceruleus at 1.5T using a 3D-gradient echo sequence with magnetization transfer contrast.
Magn Reson Med Sci.
2008; 7:205-10.
8.
McKeith IG,
Galasko D,
Kosaka K,
et al.
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology 1996; 47:1113-24.
9.
Braak H,
Del Tredici K,
Rüb U,
et al.
Staging of brain pathology related to sporadic Parkinson's disease.
Neurobiol Aging 2003; 24:197-211.
10.
Stefan T.
Schwarz,
Timothy Rittman,
et al.
T1-Weighted MRI Shows Stage-Dependent Substantia Nigra Signal Loss in Parkinson’s Disease.
Movement Disorders 2011; 29:1633-38.
11.
Hallgren B,
Sourander P.
The effect of age of the non/hemin iron in the human brain.
J Neurochem 1958; 3:41-51.
12.
Vymazal J,
Righini A,
Brooks RA,
et al.
T1 and T2 in the brain of healthy subjects,
patients with Parkinson disease,
and patients with Parkinson disease,
and patients with multiple system atrophy: relation of iron content.
Radiology 1999; 211:489-95.
13.
Kinoshita T,
Ogawa T,
Yoshida Y,
et al.
Curvilinear T1 hyperintense lesions representing cortical necrosis after cerebral infarction.
Neuroradiology 2005; 47: 647-51.
14.
Castillo M,
Scatliff JH,
Kwock L,
et al.
Postmortem MR imaging of lobar cerebral infarction with pathologic and in vivo correlation.
Radiographics 1996; 16:241-50.
15.
van den Hauwe L,
Parizel PM,
Martin JJ,
et al.
Postmortem MRI of the brain with neuropathological correlation.
Neuroradiology 1995; 37:343-9.
16.
Tovi M,
Ericsson A.
Measurements of T1 and T2 over time in formalin-fixed human whole-brain specimens.
Acta Radiol 1992; 33:400-4.
17.
Kashihara K,
Shinya T,
Higaki F Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
J Clin Neurosci 2011; 18:1093-6.
18.
Kashihara K,
Shinya T,
Higaki F.
Reduction of neuromelanin-positive nigral volume in patients with MSA,
PSP and CBD.
Intern Med 2011; 50:1683-7.